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Abstract
Long noncoding RNAs (lncRNAs) are emerging as powerful regulators of cardiac development 
and disease. However, our understanding of the importance of these molecules in cardiac fibrosis 
is limited. Using an integrated genomic screen, we identified Wisper (Wisp2 super-enhancer–
associated RNA) as a cardiac fibroblast–enriched lncRNA that regulates cardiac fibrosis after 
injury. Wisper expression was correlated with cardiac fibrosis both in a murine model of 
myocardial infarction (MI) and in heart tissue from human patients suffering from aortic stenosis. 
Loss-of-function approaches in vitro using modified antisense oligonucleotides (ASOs) 
demonstrated that Wisper is a specific regulator of cardiac fibroblast proliferation, migration, and 
survival. Accordingly, ASO-mediated silencing of Wisper in vivo attenuated MI-induced fibrosis 
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and cardiac dysfunction. Functionally, Wisper regulates cardiac fibroblast gene expression 
programs critical for cell identity, extracellular matrix deposition, proliferation, and survival. In 
addition, its association with TIA1-related protein allows it to control the expression of a 
profibrotic form of lysyl hydroxylase 2, implicated in collagen cross-linking and stabilization of 
the matrix. Together, our findings identify Wisper as a cardiac fibroblast–enriched super-
enhancer–associated lncRNA that represents an attractive therapeutic target to reduce the 
pathological development of cardiac fibrosis in response to MI and prevent adverse remodeling in 
the damaged heart.
INTRODUCTION
Acute myocardial infarction (MI) due to coronary artery disease typically leads to 
maladaptive myocardial remodeling and heart failure (HF) (1, 2). HF places a major 
economic and clinical burden on the industrialized world, accounting for more than 400,000 
deaths and more than 20 billion dollars in annual health care costs in the United States alone 
(3). Initial translational research has focused on the contracting cells of the heart, the 
cardiomyocytes (CMs), as a target in therapies aimed at restoring cardiac function. This was 
despite a wide appreciation that acute and chronic injuries trigger tissue remodeling, which 
invariably results in and is a consequence of the development of cardiac fibrosis (1). The 
destruction of the myocardium after infarction is compensated by the excessive production 
of extracellular matrix (ECM) and the formation of a collagen-rich fibrotic scar. Scar 
formation, tissue remodeling, and progressive interstitial fibrosis lead to a severe loss of 
function and ultimately HF (1, 2). Moreover, cross-linking enzymes and posttranslational 
modifications can alter collagen fibrils. This has important implications for matrix synthesis 
and degradation, which ultimately determine the onset of diastolic dysfunction (4). Despite 
this clinical importance, very few therapeutic modalities are available to prevent the 
development of HF. Antifibrotic drugs include blockers of the renin-angiotensin-aldosterone 
system and mineralocorticoid receptor antagonists but are inefficient in the vast majority of 
fibrotic diseases (5). Current medications typically slow the progression of the disease rather 
than prevent or reverse it, which could be achieved if cardiac fibroblasts (CFs) were the 
primary cell target (6). There is therefore an urgent need to develop alternative therapeutic 
strategies—for instance, targeting fibroblast differentiation into myofibroblasts or alteration 
of collagen cross-linking. To achieve this, a deeper characterization of the CF gene program 
and its associated cellular processes is required to identify specific regulatory molecules and 
targets (7, 8).
Activation and differentiation of CFs into myofibroblasts initiate the pathological process in 
the diseased heart. Myofibroblasts synthesize and secrete soluble procollagen I and III, 
which are processed by metalloproteinases, cross-linked by lysyl oxidases and hydroxylases, 
and assembled into dense fibers. The ability of myofibroblasts to resist apoptosis and secrete 
large quantities of profibrotic signaling molecules contributes to the overall pathogenesis of 
HF (1, 6). Like all differentiated cells, CF identity is hardwired by specific gene regulatory 
networks (GRNs) (7). These GRNs are controlled by core transcription factors (TFs), 
proteins that interact in a combinatorial manner at cis-regulatory sequences on DNA to 
regulate downstream programs dictating cell identity and behavior (9, 10). Enhancers, 
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regions of DNA that can be bound by TFs, represent the key information processing units 
within the genome and integrate developmental, temporal, spatial, and environmental cues 
(11). In addition, enhancers may assemble together, generating large enhancer clusters 
named super-enhancers (SEs) (10, 12, 13). These SEs have important regulatory 
characteristics, including exquisite cell/tissue specificity, and appear to be crucial for the 
maintenance of cell identity. These elements are enriched in single-nucleotide 
polymorphisms linked to common traits and diseases specific to the tissues that harbor them 
(12). These findings have led many to speculate that SEs could hold therapeutic potential, 
provided that the means of modulating their activities could be tightly controlled (10, 14).
With the recognition that the mammalian genome is predominantly non–protein-coding (15), 
the classical protein-centric view of GRN regulation appears to have been premature. RNA-
sequencing (RNA-seq) approaches have revealed that the majority of the noncoding genome 
is actively transcribed, generating thousands of small and long regulatory noncoding RNAs 
(ncRNAs) (15). Although the implication of microRNAs in the development of stress- and 
age-induced cardiac fibrosis is well documented (16–18), the more abundant and more 
diverse long ncRNA (lncRNA) group remains to be comprehensively characterized during 
heart remodeling. Despite increasing implications in CM hypertrophy and function (19–22), 
the involvement of lncRNAs in regulating cardiac fibrosis needs to be demonstrated (23). 
lncRNAs are able to regulate GRN activity via a disparate array of transcriptional and 
posttranscriptional mechanisms (24). Active enhancers are transcribed into ncRNAs, and 
SEs tend to produce more RNAs than typical enhancers (TEs) (25–27). Enhancer-associated 
lncRNAs are important for trapping TF proteins on DNA, modifying the local chromatin 
environment, and organizing nuclear three-dimensional topologies to ensure the correct 
activation of target gene programs (27, 28). Together, this suggests that targeting lncRNAs 
associated with CF-specific enhancers may represent a powerful means to modulate CF 
behavior.
In line with this hypothesis, we recently characterized the long noncoding transcriptome in a 
murine model of MI and identified hundreds of novel heart-enriched lncRNAs (29). The vast 
majority of these transcripts were associated with active heart-specific enhancers (29, 30), 
especially those dynamically modulated after MI. Some of these transcripts were conserved 
in humans and shown to be differentially expressed in cardiac disease including aortic 
stenosis (AOS) and dilated cardiomyopathy (29). These observations suggested that 
enhancer-associated lncRNAs were likely to represent interesting therapeutic targets for 
pathological fibrosis (9, 10). We therefore integrated previously generated transcriptomic 
and epigenomic data sets to identify Wisper (Wisp2 super-enhancer–associated RNA) as a 
CF-enriched lncRNA that could regulate cardiac fibrosis. Of crucial importance, WISPER is 
conserved in humans, and its expression in the human heart correlates with collagen content 
and the severity of cardiac fibrosis. These results highlight the potential for CF-specific SE-
associated lncRNAs as therapeutic targets for the amelioration of cardiac fibrosis and 
ultimately HF.
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RESULTS
Wisper is cardiac SE-associated lncRNAs
Emerging evidence suggests that SEs and the lncRNAs associated with them represent 
specific regulators of cell state and identity during development and disease (10). On the 
basis of this cogent rationale, we set out to identify SE-associated lncRNAs modulated in the 
damaged myocardium, which were conserved among mouse and human genomes (Fig. 1A). 
Previously, our laboratory identified 1521 novel lncRNAs in the murine heart (29). A large 
number of these novel lncRNAs were associated with active cardiac-specific enhancers. 
Using this transcriptomic data set, we first filtered for all novel lncRNAs that were classified 
as heart-enriched. To facilitate downstream functional assessment and alleviate any 
confounding interpretations based on overlapping protein-coding genes (PCGs), we further 
filtered lncRNAs for those that were intergenic and differentially expressed in the border 
zone (BZ) 14 days after MI, resulting in the inclusion of 149 lncRNAs (Fig. 1B). To identify 
putative human orthologs, we mapped these transcripts to the human genome using 
TransMap, a cross-species alignment tool. Globally, of these 149 mouse lncRNAs, 130 were 
predicted to have human orthologs. Considering that lncRNAs associated with TEs and SEs 
likely represent high-priority functional candidates (10), we next examined an enhancer 
catalog generated in 23 human tissues that used histone 3 lysine 27 acetylation (H3K27Ac) 
marks and the Rank Ordering of Super-Enhancers (ROSE) algorithm to identify tissue-
specific TEs and SEs (12). We found that 37 (28%) of our lncRNAs map to TEs and 6 (5%) 
mapped to human heart–specific SEs. The most up-regulated lncRNA in the infarcted mouse 
heart was one of the six SE-associated lncRNAs, supporting the notion that these transcripts 
could play important roles in the transcriptional reprogramming that underpins cardiac 
remodeling (Fig. 1C). To dissect the cardiac cell specificity of the six SE-associated 
lncRNAs, we evaluated the expression in CFs and CMs isolated from the adult murine heart. 
Expression of these transcripts and canonical PCGs was determined via quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) (Fig. 1D). The CM-specific PCGs, 
Tnni3 and Actc1, were highly enriched in CM preparations, whereas CF-specific PCGs, 
Col1a1, Tgfb2, Postn, and Vim, were specifically enriched in CFs. Among the SE-associated 
lncRNAs, two were significantly enriched in CMs (P = 0.009 and 0.42, respectively), 
whereas one lncRNA was highly enriched in CFs (P < 0.001). This transcript was more 
enriched in CFs than the CF-specific PCGs, suggesting that it could have important 
functions in this particular cardiac cell type and therefore could play a role in the fibrotic 
response of the heart after infarction. Proximal to this lncRNA was the gene encoding the 
matricellular protein Ccn5 (Wisp2), which had recently been implicated in pathological 
myocardial fibrosis (31). We therefore named this lncRNA Wisper and its human ortholog 
WISPER. This transcript was found to be substantially conserved in the two species with a 
57.3% sequence identity between the two orthologs (fig. S1, A to C). The SE from which 
this lncRNA was derived was uniquely active in the adult human heart as compared to other 
tissues (Fig. 1E). Nevertheless, the SE overlapped with WISP2 sequences, suggesting that it 
contains several constituent enhancers, which may encode a different cis-regulatory potential 
(32). Considering the enrichment of this transcript in CFs, coupled to its up-regulation in the 
BZ after MI, we suspected that it could represent an interesting target molecule for the 
regulation of pathological fibrosis and was selected for further investigation.
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Wisper expression is enriched in CFs and associated with cardiac fibrosis
Integrative transcriptome analysis using publicly available RNA-seq data sets demonstrated 
that Wisper was a heart-enriched transcript (29). To validate this finding, we conducted qRT-
PCR using RNA isolated from different adult mouse tissues. Wisper was more expressed in 
the heart than in all other tissues (Fig. 2A). On the other hand, Wips2 expression was not 
characterized by the same tissue distribution. We next quantified Wisper expression in 
fibroblasts of cardiac and noncardiac origins. In comparison to fibroblast-associated PCGs 
such as Tgfb2, Fn1, Col3a1, and Col1a1, which were similarly expressed in fibroblasts from 
different sources, Wisper was significantly enriched in fibroblasts isolated from neonatal and 
adult hearts (Fig. 2B; P < 0.001). Several binding sites for cardiac TFs such as GATA4 and 
NKX2–5 were identified in the SE element from which WISPER derives (fig. S1D). This 
was in contrast to WISP2, which was characterized by distinct TF binding sites at its 
promoter such as ATOH1 binding sites and E-box, which were known to regulate lung-
specific expression (fig. S1E) (33). Finally, lncRNA functions are typically dependent on 
subcellular localization, with those present primarily in the nucleus involved in chromatin 
regulation, whereas cytoplasmic lncRNAs influence posttranscriptional processes (24). 
Wisper was found to be equally distributed between the two sub-cellular compartments, 
indicating that it could play roles in both transcriptional and posttranscriptional regulatory 
processes (Fig. 2C).
After MI, the myocardium undergoes a remodeling process that is characterized by three 
distinct phases. These include an inflammatory response (days 1 to 3 after injury), 
proliferation and granulation tissue formation (days 7 to 14), and scar maturation (days 21 to 
28) (34). Profibrotic pathways are typically associated with the proliferative phase, in which 
differentiation of myofibroblasts and subsequent proliferation, migration, and secretion of 
ECM components take place. To assign Wisper to either of these phases, MI was induced in 
the mouse heart by ligation of the left anterior descending (LAD) artery and Wisper 
expression was assessed over a 28-day period. Cardiac dimensions and function were 
assessed by echocardiography (Fig. 2D and table S1). Gene expression profiling 
demonstrated the expected expression kinetics for fibrotic and hypertrophy-associated PCGs 
(Fig. 2E). Wisper was maximally expressed 14 days after MI, corresponding to the 
proliferative phase in which myofibroblasts migrate to the BZ and actively secrete collagen 
and other ECM components. The temporal kinetics of Wisper induction implicated this 
transcript in cardiac fibrosis driving pathological remodeling. To support these findings, we 
perfomed RNA in situ hybridization using probes against Wisper on mouse hearts 14 days 
after infarction. In accordance with Wisper expression in activated fibroblasts, a marked 
signal was observed in the BZ of infarcted hearts (Fig. 2F and fig. S2A). Wisper expression 
was also detected, albeit less frequently, in the interstitial space of the viable muscle. We 
therefore evaluated whether Wisper expression correlated with gene programs linked to 
cardiac fibrosis. Wisper expression was highly correlated with PCGs relevant to ECM 
deposition (Fig. 2G) and also highly correlated with echocardiographic traits linked to 
remodeling of the injured myocardium (Fig. 2H). Moreover, to evaluate the tissue specificity 
of Wisper expression under stress conditions, we used a mouse model of renovascular 
hypertension, namely, the one-kidney, one-clip (1K1C) model (35). Cardiac hypertrophy and 
fibrosis develop in response to volume overload in this model (fig. S2, B to D). In addition, 
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the single hypoxic kidney is also characterized by extensive fibrosis (fig. S2D). Strikingly, 
Wisper was induced in the stressed heart but not in the stressed kidney. In contrast, Wisp2 
expression was up-regulated in both organs.
Wisper controls CF behavior and survival
To characterize the functional role of Wisper, a loss-of-function approach was used in 
isolated adult murine CFs. Modified antisense oligonucleotides (ASOs) called GapmeRs 
were used to initiate nuclear ribonuclease H–mediated degradation of the transcript and to 
deplete Wisper in both the nucleus and cytoplasm (fig. S1A). Titration experiments showed 
that 10 nM GapmeRs targeting Wisper was sufficient to achieve maximal knockdown in 
adult CFs without affecting CF integrity (Fig. 3A). This concentration was therefore used for 
subsequent experiments. Silencing of Wisper expression resulted in a specific impact on 
ECM-associated PCG expression (Fig. 3B). Col3a1, Fn1, and Tgfb2 were down-regulated; 
however, Col1a1 and Ctgf were not affected. Wisper depletion also led to the down-
regulation of the proximal PCG Wisp2, suggestive of a possible cis-regulatory role in adult 
CFs. Considering the effect on gene expression, we suspected that Wisper could be 
fundamentally involved in the transdifferentiation of CFs into myofibroblasts. We therefore 
isolated neonatal murine CFs, which can be induced to differentiate through cell passaging 
in vitro. Differentiation of these cells resulted in the up-regulation of myofibroblast-specific 
PCGs such as Tgfb2, Fn1, Col1a1, Col3a1, and aSma [also known as Acta2] (fig. S3A). 
Wisper and Wisp2 expression was closely associated with myofibroblast differentiation. 
Wisper depletion in differentiated myofibroblasts resulted in a significant down-regulation of 
Col3a1, Fn1, Tgfb2, and aSma expression (fig. S3B; P < 0.001), similar to what was 
observed in adult CFs (Fig. 3B). The myofibroblast-associated α-smooth muscle actin (α-
SMA) protein was also significantly down-regulated (fig. S3C; P = 0.011). Again, Col1a1 
was not affected by Wisper depletion, supporting a specific regulatory role on individual 
ECM genes.
Because Wisper depletion was found to have a large impact on fibroblast identity, we 
proceeded to evaluate cell behavior after Wisper knockdown in adult CFs. We found a 
significant decrease in proliferation in CFs 24 hours after Wisper knockdown (Fig. 3C; P < 
0.001), suggesting that Wisper was important for the proliferative ability of CFs. Using a 
wound closure assay, we demonstrated a significant attenuation of the migratory ability of 
Wisper-depleted CFs (Fig. 3D; P < 0.001). Finally, apoptosis was assessed in Wisper-
depleted CFs via testing annexin V positivity by flow cytometry analysis. At 24 hours after 
transfection, there was a fivefold increase in the percentage of apoptotic CFs treated with 
GapmeRs targeting Wisper (Fig. 3E). In addition, the ratio between Bax and Bcl2 expression 
indicated an increase in proapoptotic signaling in CFs upon Wisper depletion (Fig. 3F). 
Together, these data suggest that Wisper knockdown affects cell survival in CFs. To confirm 
the cardiac specificity of Wisper function, we used the same dose of Wisper-targeting 
GapmeRs in fibroblasts of noncardiac origin, that is, lung fibroblasts (Fig. 3G), and observed 
no impact on the expression of fibroblast-associated PCGs (Fig. 3H), proliferation (Fig. 3I), 
migration (Fig. 3J), and apoptosis (Fig. 3K). Finally, despite being largely CF-enriched, 
Wisper is also expressed at low concentrations in CMs. Therefore, we also tested the effects 
of GapmeRs in neonatal CMs to detect any unanticipated effects on these cells (fig. S3D). 
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Although GapmeR treatment slightly decreased Wisper expression, it did not affect CM-
specific gene expression, structure, cross-sectional area, or cell number. The number of CFs, 
which are typically present in neonatal CM cultures, was reduced after Wisper depletion, 
suggesting that decreased Wisper expression in CM cultures reflects modulation in 
contaminating CFs.
Wisper regulates specific CF gene programs
To determine whether Wisper played a global role in the regulation of specific CF gene 
programs, RNA-seq was performed on scrambled and Wisper-specific GapmeR-treated adult 
CFs. We identified 3153 differentially expressed PCGs (fold change, >2; adjusted P value, 
<0.05) in Wisper-depleted CFs, of which 1337 were up-regulated and 1816 were down-
regulated (Fig. 4A). Using Gene Ontology (GO) analysis, we found that up-regulated PCGs 
were associated with biological processes linked to the control of cell cycle and mitosis (Fig. 
4B). Furthermore, these PCGs were also associated with mouse phenotypes linked to 
abnormal control of cell cycle and induction of cell death, both processes observed in 
Wisper-depleted CFs. Down-regulated PCGs were associated with modulation of the 
immune response and inflammatory phenotypes in the mouse (Fig. 4C). These findings are 
consistent with the important roles that CFs play during acute inflammation after infarction 
(34). Up-regulated genes included many important proapoptotic molecules (for example, 
Dusp6 and Casp3), whereas antiapoptotic genes were down-regulated (for example, Bcl2l1 
and Bcl2a1b) (Fig. 4D). Similarly, cell cycle inhibitors (for example, Btg1 and Tob1) were 
induced upon Wisper deletion, whereas cell cycle activators (for example, Ccnd1) were 
down-regulated. Many regulators of the immune response were also down-regulated (for 
example, Cxcl10). Key PCGs linked to the ECM (for example, Col4a6 and Col8a1) were 
depleted in Wisper GapmeR-treated cells. Furthermore, we also tested the capacity of 
Wisper to induce a fibroblastic gene program in nonfibroblastic cells when enacted at its 
own site of transcription. We used a CRISPR (clustered regularly interspaced short 
palindromic repeats)–based gain-of-function approach (CRISPR-on). P19CL6 cells were 
transfected with components of the synergistic activation mediator described by the Zhang 
laboratory in combination with a Wisper-targeting guide RNA engineered to contain two 
MS2 aptamers (36). Significant Wisper expression was measured 2 days after transfection (P 
< 0.011). In turn, prototypic fibroblast genes were induced. Wisp2 was not activated in these 
cells (Fig. 4E). Considering the cis-based regulatory roles linked to SE-associated lncRNAs, 
we proceeded to assess the impact of Wisper depletion on proximal PCGs embedded within 
its topologically associated domain (TAD). Cell type–invariant TADs are typically 
established during pluripotency and are critical for configuring the three-dimensional 
chromatin architecture that ensures correct temporal and spatial interactions between distal 
enhancers and their target promoters. We therefore used publicly available high-throughput 
confirmation capture data sets from mouse embryonic stem cells to interrogate the 
topological nature of this locus (fig. S4A). Of the 10 PCGs within the Wisper-harboring 
TAD, 5 were differentially expressed upon Wisper depletion in adult CFs, one of which is 
Wisp2. We therefore evaluated whether Wisper could exert its action via cis-regulation of 
Wisp2 expression. We examined the specificity of the gene expression programs in CFs after 
GapmeR-mediated Wisp2 depletion, which resulted in a significant loss of Wisp2 expression 
(P < 0.001) without affecting Wisper concentrations (Fig. 4F). The canonical ECM proteins 
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previously examined, whose expression was modified by Wisper depletion, were not 
affected by Wisp2 knockdown. These data support a role for Wisper in dictating gene 
programs associated with cell identity and behavior in CFs, independent of Wisp2 
expression. Finally, the RNA-seq data also allowed us to assess the impact of Wisper 
depletion on the annotated long noncoding transcriptome (fig. S4B). Among the 435 up-
regulated IncRNAs, well-characterized IncRNAs such as Neat1 and Gas5 were included (fig. 
S4C). Conversely, 276 IncRNAs were down-regulated; among them, Malat1, Ftx, and Firre 
have all been implicated in cell cycle control and apoptosis in various cell types (37, 38).
Wisper is associated with TIA1-related protein and regulates lysyl hydroxylase 2 
expression
Many IncRNAs exert their function via interaction with proteins. To identify relevant 
Wisper-binding proteins, we performed an IncRNA pulldown assay. A biotinylated Wisper 
probe was therefore used as a bait to selectively extract putative Wisper protein partners 
from an adult CF lysate (fig. S4, D and E). An antisense Wisper transcript was used as 
control. Then, proteins were identified by shotgun mass spectrometry. Four proteins were 
detected as specifically associated with Wisper, namely, TIAR, PTB3, DIS3L2, and CELF2 
(Fig. 5A). All four RNA binding proteins have been implicated in RNA processing. TIAR, 
PTBP3, and CELF2 are splicing factors, and DIS3L2 has been involved in target mRNA-
mediated microRNA degradation as well as mRNA decay (39–43). These proteins 
demonstrate relevant functions as regulators of differentiation, proliferation, and apoptosis 
during development and in adulthood. Nevertheless, protein inference based on peptide 
analysis unambiguously identified TIAR [TIAl-related protein, also referred to as TIA1 
cytotoxic granule-associated RNA binding protein-like 1 (TIAL1)] as a prime candidate with 
26% amino acid coverage (102 of 392; Fig. 5B). More importantly, TIAR has been related to 
tissue fibrosis via its capacity to regulate expression of lysyl hydroxylase 2 [also known as 
procollagen lysine, 2-oxoglutarate 5-dioxygenase (Plod2)] (44) and thereby the extent of 
collagen cross-linking. We confirmed the strong association of TIAR with Wisper using 
Western blotting to detect TIAR after Wisper pulldown (Fig. 5C). Then, we performed an 
RNA immunoprecipitation assay to validate Wisper-TIAR interaction (Fig. 5D). RT-PCR 
after TIAR immunoprecipitation detected Wisper and Plod2 as TIAR-bound transcripts but 
not Wisp2. Wisper knockdown reduced the amounts of TIAR-associated Wisper as expected 
and, in addition, also affected the amounts of TIAR-bound Plod2 (Fig. 5D). Down-
regulation of Wisper expression in CFs therefore resulted in decreased Plod2 expression, 
whereas Wisp2 depletion did not change Plod2 concentrations (Fig. 5E). TIAR has been 
demonstrated to shuttle between the cytoplasm and the nucleus (45). Because Wisper was 
also found in both the cytoplasm and the nucleus, we investigated whether TIAR nuclear 
translocation could depend on Wisper action. Primary CFs were therefore transfected with 
Wisper-targeting GapmeRs, and TIAR subcellular localization was determined by 
immunostaining (Fig. 5, F to H). Wisper knockdown resulted in a dose-dependent decrease 
in the number of fibroblasts with nuclear TIAR staining. Confocal microscopy confirmed the 
absence of TIAR in the nucleus and retention of the protein in the cytoplasm of treated cells.
Micheletti et al. Page 8
Sci Transl Med. Author manuscript; available in PMC 2017 October 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Preventive Wisper depletion in vivo inhibits cardiac fibrosis
To test whether the antifibrotic effects of Wisper in cultured CFs may hold therapeutic 
potential in cardiac fibrosis, we performed loss-of-function experiments in mice. We first 
completed a dose escalation study in adult untouched mice by administering Wisper 
GapmeRs (5, 10, and 15 mg/kg) (fig. S5A). Control mice received a scrambled GapmeR at a 
dose of 10 mg/kg. All mice injected with 15 mg kg died within the first week after GapmeR 
injection, whereas the 5 and 10 mg/kg doses had no impact on survival (fig. S5B). 
Echocardiography performed at 4,14, and 28 days after injection showed that mice receiving 
Wisper GapmeRs (10 mg/kg) demonstrated signs of cardiac remodeling, particularly a 
thickening of the interventricular septum. Animals injected with 5 mg/kg were not different 
from controls (fig. S5C and table S2). To determine the impact of acute and massive Wisper 
depletion on cardiac dimensions and function, we performed echocardiography in untouched 
mice receiving Wisper GapmeR (15 mg/kg) 4 days after injection. At this time point, the 
myocardium exhibited structural alterations, including an increased thickness of the 
ventricular septum and of the posterior wall, with a concomitant reduction of the left 
ventricular cavity. This peculiar situation was characterized by a paradoxical increase in EF, 
associated to a largely decreased stroke volume, creating a very detrimental situation (fig. 
S5D). Wisper was significantly depleted in isolated adult CFs (P < 0.007), and a robust 
down-regulation of key PCGs, including Collal, Col3al, Vim, and Postn, was also observed 
(fig. S5, E and F). Finally, a significant up-regulation of cardiac stress markers, including 
Ctgf and Myh7 (P = 0.012 and 0.011, respectively), was measured. Despite a dramatic 
decrease of collagen expression in the heart in animals receiving this toxic dose of Wisper 
GapmeRs, no effects on collagen expression were observed in the kidneys or the liver (fig. 
S5G). Signs of liver damage were, however, evident because plasma concentrations of both 
aspartate aminotransferase and alanine aminotransferase were elevated (fig. S5H). The 
amounts of these enzymes in the blood of mice receiving 5 mg/kg were not changed, 
indicating no toxic effects of Wisper GapmeR at this concentration. On the basis of these 
data, the 5 mg/kg dose was therefore selected for subsequent experiments in vivo.
We used GapmeRs to perturb the induction of Wisper in a preventive strategy by delivering 
scrambled and Wisper-targeting GapmeRs 3 days before the induction of MI and assessed 
cardiac function 7 and 14 days after MI (fig. S6A). RNA was isolated and histological 
sections were generated 14 days after infarction. Consistent with the observed effects in 
vitro, delivery of Wisper GapmeR resulted in the blunted expression of Wisper in the heart 
(fig. S6B) and of key ECM-associated PCGs (fig. S6C). Wisper was not affected by 
GapmeR treatment in sham-operated animals, suggesting that only stress-stimulated Wisper 
expression was sensitive to knockdown using a dose of 5 mg/kg. Gene expression was 
measured more than 2 weeks after GapmeR administration. Compared to scrambled 
GapmeR-treated animals, mice treated with Wisper GapmeR exhibited improved structural 
and functional parameters at 7 and 14 days after MI, as assessed by echocardiography (fig. 
S6, D and E, and table S3). Wisper-depleted mice demonstrated decreased remodeling, as 
indicated by decreased heart weight–to–tibial length ratio (fig. S6F). Infarct size was 
reduced and a significant decrease in myocardial fibrosis was observed (fig. S6G; P = 
0.006). Considering the impact of Wisper depletion on CF proliferation in vitro, we also 
assessed nonmyocyte cell proliferation in vivo via 5-bromo-2’-deoxyuridine (BrdU) 
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incorporation. The reduced numbers of BrdU-positive nonmyocyte cells in Wisper GapmeR-
treated animals were indicative of decreased proliferation in this subpopulation (fig. S6H). 
However, despite these largely beneficial effects of Wisper depletion on maladaptive 
remodeling, decreased CF survival before injury may also be expected to affect the acute 
wound healing process. We observed that Wisper GapmeR-treated mice exhibited a higher 
rate of mortality during the acute phase after MI, primarily resulting from left ventricular 
wall rupture, suggesting that Wisper silencing might impair the acute would healing process 
that relies on CF activity (fig. S6I). This prompted us to test the therapeutic potential of 
Wisper depletion in a therapeutic protocol more relevant for a clinical setting.
Therapeutic depletion of Wisper in vivo inhibits cardiac fibrosis and improves function
To evaluate the potential utility of Wisper targeting as an antifibrotic therapy, we used a 
therapeutic protocol in which Wisper was depleted after MI. MI was induced and Wisper 
GapmeRs were injected 2 and 9 days after injury to avoid affecting acute wound healing and 
to subsequently modulate the evolution of the pathological proliferative phase of the 
remodeling process (Fig. 6A). Cardiac dimensions and function were assessed by 
echocardiography at 7 and 28 days after MI. RNA was isolated upon sacrifice at 28 days, a 
temporal point coinciding with the evolution of the mature scar and the development of 
pathological remodeling. Both Wisper and its proximal PCG Wisp2 demonstrated blunted 
cardiac expression in Wisper GapmeR-treated mice (Fig. 6B). This profile was associated 
with a significant impact on the expression of key ECM and profibrotic PCGs including 
Tgfb2 (P = 0.003), Collal (P = 0.007), CoBal (P = 0.010), Fnl (P = 0.010), and aSma (P = 
0.021) (Fig. 6C and fig. S7A). Additionally, expression of cardiac stress markers was also 
blunted upon Wisper silencing, suggestive of a beneficial impact on cardiac hypertrophy 
(fig. S7A). At both 7 and 28 days after MI, Wisper-depleted mice exhibited significantly 
improved cardiac function (Fig. 6E) (%FS: P = 0.008 and 0.004 at 7 and 28 days, 
respectively) and decreased remodeling (Fig. 6, D to F, and table S4). This response was 
associated with a reduction in infarct size and a significant perturbation of cardiac fibrosis 
(Fig. 6G; P = 0.002), resulting in preserved tissue architecture and reduced thinning of the 
myocardial wall after Wisper knockdown. In support of this, postinfarction fibrosis was 
found to be highly correlated with Wisper expression in treated mice and even more highly 
correlated with the expression of canonical ECM associated PCGs such as Collal and CoBal 
(Fig. 6H). Mortality rate in treated animals was not augmented during the acute phase, 
indicating that the wound healing process was not negatively affected (Fig. 6I). Wisper-
depleted mice had a slightly increased survival rate after injury when compared to controls, 
suggestive of an overall beneficial effect on mortality rates. Collectively, these data support 
an important role for Wisper in pathological cardiac fibrosis and demonstrate that 
therapeutic targeting of Wisper after MI elicits clinically desirable effects.
WISPER expression correlates with the extent of fibrosis in the diseased human heart
A putative ortholog of Wisper was identified in the human genome, mapping to an LV-
specific SE (Fig. 1E and fig. S1, A to C). Primers were designed to amplify this transcript, 
which could be consistently detected in RNA isolated from human cardiac biopsies, 
formally demonstrating that WISPER was evolutionary conserved. We therefore proceeded 
to quantify WISPER expression in RNA isolated from the interventricular septum of patients 
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suffering from AOS (table S5). AOS is associated with extensive myocardial fibrosis that 
directly contributes to LV dysfunction. In cardiac samples from all AOS patients, the 
collagen volume fraction (CVF) was higher than that in samples from healthy volunteers 
(46). After analyzing the distribution of CVF in the AOS cohort, two groups were identified: 
a group with nonsevere fibrosis (n = 11) with a CVF lower than 12% and a severe fibrosis 
group (n = 15) with a CVF greater than 12%. WISPER expression, and not the expression of 
its proximal PCG WISP2, was significantly increased in the severe fibrosis group (Fig. 7A; 
P = 0.012 and 0.120, respectively). Moreover, in a correlation analysis, WISPER expression 
and not WISP2 was found to be associated with the degree of CVF in all AOS patients (Fig. 
7B). To evaluate the functional importance of WISPER in human fibroblasts, we used 
human dermal fibroblasts and human CFs. Both cell types can be induced to differentiate 
into myofibroblasts via serum starvation. This process is associated with the up-regulation of 
COL1A1, COL3A1, and aSMA in both fibroblast populations (fig. S7, B and C). WISPER 
was significantly induced by serum starvation in CFs but not in dermal fibroblasts (Fig. 7C; 
P < 0.001). WISP2 was also up-regulated in differentiating CFs. Supporting observations in 
the mouse, WISPER expression was correlated with COL3A1, FN1, and aSMA expression 
in differentiating human CFs (Fig. 7D). The functional importance of WISPER was tested in 
knockdown experiments. WISPER depletion using GapmeRs resulted in decreased 
expression of COL1A1, COL3A1, FN1, and aSMA in human CFs (Fig. 7E). Silencing of 
WISPER did not affect WISP2 expression, suggesting again that WISPER controls fibrotic 
gene expression independently of WISP2. Finally, PLOD2 expression was decreased in 
human CFs after GapmeR-mediated WISPER depletion (Fig. 7F). These findings 
demonstrate that WISPER is an IncRNA conserved in humans and highlight the translational 
relevance of WISPER as a therapeutic target in cardiac fibrosis.
DISCUSSION
After MI, activated CFs and associated ECM production assume crucial roles during the 
acute and chronic phases of the adaptive response of the heart to new hemodynamic 
conditions (1). However, maladaptive changes in ECM dynamics lead to the long-term 
disruption of myocardial architecture and function, eventually leading to HF. Excessive 
ECM deposition and its adverse effects are potentially modifiable (5, 34); a reduction in the 
development of fibrosis can be observed in humans treated with therapeutics aimed at 
limiting pathological remodeling of the diseased heart (5). Because of the nontargeted nature 
of these approaches, beneficial effects on fibrosis are relatively modest. Nonetheless, these 
agents improved clinical outcomes, providing a strong rationale for the development of 
highly specific therapeutics directly targeting the CF population.
The goal of this study was to identify fibrosis-associated therapeutic targets. We focused on 
the enhancer landscape and their associated transcripts and discovered the evolutionary 
conserved SE-associated IncRNA that we named Wisper, a polyadenylated and multiexonic 
CF-enriched transcript. Although the human genome encodes thousands of polyadenylated 
multiexonic IncRNAs, their functional and translational importance in controlling 
pathological remodeling and fibrosis remains largely unexplored. In contrast, the roles of 
IncRNAs in cardiogenesis and in maintaining identity in adult CMs are emerging, 
supporting their translational importance as therapeutic targets in the diseased adult heart 
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(16, 47). We recently demonstrated that developmental enhancer–associated IncRNAs are 
reexpressed in stressed mouse and human hearts, potentially as part of a reactivation of a 
fetal gene program under pathological conditions (19, 30). The IncRNA Mhrt, which is 
associated with the Myh7 locus, was shown to protect the heart from hypertrophy and failure 
(20). Two other IncRNAs, Chast and Chaer, have recently been shown to play important 
roles during maladaptive cardiac remodeling (21, 48). Down-regulation of Chast after 
GapmeR administration can prevent tissue remodeling or even induce its regression after 
stress. Although extremely encouraging, these transcripts are primarily CM-enriched. 
Therefore, although their modulation produces beneficial effects on pathological fibrosis, 
they do not specifically control CF biology. Wisper, on the other hand, is a highly CF-
enriched IncRNA. Furthermore, Wisper depletion leads to a global transcriptional 
reprogramming of the networks controlling proliferation, migration, apoptosis, and 
differentiation solely in CFs. Considering its distribution within both the cytoplasm and 
nucleus, Wisper could exert its action via both cis- and trans-regulatory functions, 
presumably via interaction with nuclear and cytoplasmic RNA binding proteins. In this 
context, we identified TIAR as a Wisper-associated protein. TIAR plays an important role in 
strengthening alternative 5′ splice sites (49). PLOD2 has two splice variants with the long 
form containing an additional exon, whose inclusion is controlled by TIAR. TIAR has been 
therefore implicated in tissue fibrosis via its capacity to promote production of the long 
profibrotic PLOD2 form (44). The short form is not expressed in the heart. Moreover, both 
Wisper and Plod2 bind TIAR, and down-regulation of Wisper in CFs decreases TlAB/Plod2 
interaction and Plod2 expression, suggesting that Wisper regulates Plod2 mRNA 
posttranscriptional processing and its cellular concentrations via controlling Plod2 
association with TIAR. PLOD2 has also been shown to induce collagen synthesis 
independently of its action on cross-linking and stabilization of the matrix (50), further 
supporting a central role for TIAR and PLOD2 in fibrosis. In addition, TIAR is a 
multifunctional protein that dictates many aspects of RNA metabolism. TIAR functionally 
interacts with ncRNAs, including IncRNAs (51, 52). IncRNA-mediated regulation of TIAR 
is therefore emerging as a common mechanism to confer context and cell specificity on an 
otherwise ubiquitously acting system. In particular, TIAR has been implicated in the control 
of cell proliferation and apoptosis. The GO terms associated with the transcriptional 
programs after Wisper knockdown are highly reminiscent of the GO terms associated with 
modulated genes in response to TIAR knockdown (53). In this context, Wisper functions, in 
part, by controlling TIAR shuttling into the nucleus (45). Blocking nuclear translocation of 
TIAR in Wisper-depleted cells is therefore expected to produce global effects on fibroblast 
gene programs. Three other proteins were identified by mass spectrometry after Wisper 
pulldown. PTBP3, DIS3L2, and CELF2 demonstrate relevant functions as regulators of 
differentiation, proliferation, and apoptosis (41–43). Their roles in CFs, and in particular in 
the development of fibrosis, have not been investigated. These candidates therefore warrant 
further characterization. It is important to note, however, that many IncRNAs are associated 
with RNA processing factors involved in maturation of the primary transcripts via 
posttranscriptional modification. Association of these proteins with a multiexonic IncRNA 
such as Wisper might also reflect the need for this transcript to be appropriately processed 
for ensuring its functions. In this regard, TIAR, while being a splicing factor, is the only 
protein of this small group with a demonstrated link to fibrosis.
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The extent of gene reprogramming in fibroblast after Wisper knockdown demonstrates that 
Wisper exerts several important functions, some of which are probably independent of 
TIAR. We therefore examined the expression of genes topologically associated within the 
Wisper locus. Among those, Wisp2 is comodulated with Wisper during fibroblast 
differentiation and after Wisper knockdown, suggesting that Wisper could directly control its 
proximal coding gene in cis. However, several pieces of evidence indicate that concomitant 
expression of Wisper and Wisp2 does not necessarily reflect cis-regulation. Although Wisper 
knockdown in mouse CFs in vitro induces Wisp2 down-regulation, this effect is not 
observed in human CFs. In addition, the expression signature after Wisp2 loss of function in 
CFs is distinct from that observed after Wisper knockdown, suggesting that Wisper effects 
are not mediated via Wisp2. Moreover, CRISPR-on–mediated induction of Wisper 
expression at its site of transcription does not activate Wisp2 expression. Finally, Wisp2 is 
highly expressed in the lungs where modest Wisper expression is observed. The reason for 
Wisp2 being highly expressed in this organ is possibly related to the presence, in its 
promoter, of binding sites for TFs that are known to induce lung-specific gene programs. In 
the heart, Wisp2 has recently been implicated in the therapeutic regression of cardiac fibrosis 
(31). Wisp2 appears to act therefore more as a compensatory molecule that limits the extent 
of fibrosis rather than as a promoter of fibrosis. We therefore believe that Wisp2 down-
regulation in the heart occurs secondary to Wisper depletion as a direct consequence of the 
induced beneficial impact on cardiac fibrosis.
Unlike most tissues in which myofibroblasts undergo apoptosis or revert to a quiescent state 
in the absence of pathological stress, this does not occur in the heart. However, GapmeR-
mediated depletion of Wisper before MI attenuates pathological fibrosis and remodeling. 
Nevertheless, preventive Wisper depletion also negatively affects the acute wound healing 
process, resulting in cardiac rupture and increased mortality. Loss of CFs in the stressed 
heart affects the matrix that is key for the homeostatic maintenance of myocardial integrity 
(6). CFs produce the collagenous matrix that prevents myofiber slippage and sustains 
ventricular chamber geometry under normal conditions; interfering with this process results 
in weakening of the ventricular wall and susceptibility to rupture. Along the same lines, it is 
likely that massive doses of anti-Wisper GapmeRs destabilize the delicate architecture of the 
normal heart, leading to cardiac dysfunction. This has been observed in other situations in 
which important modulators of fibrosis, such as muscleblind-like1 (MBNL1), are down-
regulated during the acute phase of the response to infarction (54). MBNL1 is an RNA 
binding protein that regulates transcripts that promote myofibroblast differentiation, and 
mice lacking MBNL1 develop cardiomyopathy with reduced function.
The detrimental effects of the Wisper GapmeR treatment during the acute phase could be 
overcome when using a therapeutic protocol in which GapmeRs were administered 2 days 
after infarction. Wisper knockdown during this clinically relevant window of time did not 
negatively affect acute wound healing while still blunting pathological fibrosis, reducing 
remodeling, and improving cardiac function at 7 and 28 days after infarction. These data 
coupled with the observation that human WISPER expression is correlated with fibrosis in 
AOS patients support translation into clinical scenarios. Clearance of activated CFs from the 
diseased heart appears to be a highly efficient process leading to progressive reduction of 
pathological fibrosis and diminished incidence of HF (5, 6). One could also envisage Wisper 
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being targeted in the context of unchecked reactive fibrosis in the myocardium 
independently of the underlying disease etiology. This could be of high clinical relevance 
because myocardial fibrosis persists in patients with HF even when treated according to 
current guidelines and correlates with mortality. An important finding in our study is the 
apparent cardiac specificity of Wisper expression. Under basal conditions, Wisper is clearly 
a CF-enriched transcript. Cardiac TF binding sites in the SE element provide an explanation 
for this interesting feature. Along this vein, data obtained in the renovascular hypertensive 
model are quite informative. Both the heart and the kidney develop severe fibrosis, but 
Wisper is only induced in the heart. This observation suggests that, in the stressed kidney, 
fibrosis is not Wisper-dependent. Nevertheless, we cannot exclude the possibility that 
Wisper expression could be induced in other cell types and/or tissues. This certainly 
warrants further investigation. Finally, our data also demonstrate that Wisper is potentially a 
highly sensitive marker for pathological fibrosis. Considering the ability to detect IncRNAs 
circulating in human plasma (55), measurement of circulating WISPER concentrations 
might provide a noninvasive means to monitor cardiac remodeling. We have previously 
analyzed a series of novel IncRNAs including Wisper and correlated their expression with 
echocardiographic traits after infarction, supporting the notion that these transcripts may 
represent interesting marker candidates (29). Together, the identification of this CF-specific 
regulatory molecule therefore represents an important step toward the development of 
targeted antifibrotic therapeutic approaches and diagnostic tools.
MATERIALS AND METHODS
Study design
The main goal of our study was to evaluate cell-specific IncRNAs as therapeutic targets for 
cardiac fibrosis and heart disease. Using a stringent pipeline, we selected high-priority 
IncRNA candidates that are associated with cardiac-specific SEs. We focused our attention 
on one CF-enriched IncRNA named Wisper. Loss-of-function experiments were performed 
to assess the role of Wisper in the biology of CFs and in fibrosis. Modified ASOs 
(GapmeRs) were used to silence Wisper expression in mouse CFs. Knockdown experiments 
were performed in human CFs to verify the evolutionary conserved function of this 
transcript. For experiments in vivo, LAD artery ligation was chosen as a well-established 
animal model of MI. Experimental groups include at least six animals to robustly identify 
alteration in cardiac function and fibrosis. Mice were randomly assigned to treatment 
groups. To test whether Wisper may hold therapeutic potential in cardiac fibrosis, we 
performed loss-of-function experiments in vivo via GapmeR injection. In the preventive 
approach, injection was performed 3 days before MI. In the therapeutic approach, GapmeRs 
were injected 2 and 9 days after infarction. GapmeR injection and echocardiographic 
measurements were double-blinded until statistical analysis. Cardiac fibrosis was quantified 
by Masson’s trichrome staining on heart sections. All sample measurements were blinded. 
In addition, to evaluate the tissue specificity of Wisper expression, we took advantage of the 
1K1C model of renovascular hypertension in the mouse. This model is characterized by the 
development of cardiac hypertrophy and fibrosis secondary to volume-dependent 
hypertension. Fibrosis also develops in the clipped kidney, allowing direct comparison of 
Wisper expression in two different fibrotic organs. WISPER human ortholog was identified 
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and detected in RNA isolated from human cardiac biopsies of patients suffering from AOS 
(all primers are listed in table S6). This pathology is associated with extensive myocardial 
fibrosis that directly contributes to LV dysfunction and HF. Samples of cardiac tissue from 
AOS patients (n = 26) were divided into two groups after analyzing the distribution for CVF, 
as described in the text. No data were excluded in this analysis.
RNA-seq–based lncRNA profiling after MI
RNA-seq on infarcted and sham-operated hearts (14 days after infarction), ab initio 
transcript reconstruction, differential expression analysis of IncRNAs, heart specificity 
analysis, and human ortholog identification data sets were previously described (29).
SE mapping to human IncRNA orthologs
The locations of SEs were downloaded from (12). These regions were defined using 
H3K27ac chromatin immunoprecipitation sequencing from the Epigenome Roadmap (56). 
IncRNAs arising from SEs and TEs were determined by genomic overlap.
Animal experiments
Animal experiments were approved by the Government Veterinary Office (Lausanne, 
Switzerland) and performed according to the University of Lausanne Medical School 
institutional guidelines.
MI model—MI in mice (numbers of animals per group are in the figure legends) was 
induced as previously described (57). Briefly, male C57BL/6 mice (Charles River) at 12 
weeks of age were anesthetized by intraperitoneal injection of ketamine/xylazine/
acepromazine (65/15/2 mg/kg) and placed on artificial ventilation. After left thoracotomy, 
the pericardium was gently opened and a 7.0 silk ligature (Aesculap) was tied around the 
LAD artery near the insertion of the left auricular appendage. Occlusion of the artery was 
verified by the rapid blanching of the LV. In sham-operated mice, the ligature was placed in 
an identical location but not tied. After surgery, mice were gradually weaned from the 
respirator until spontaneous respiration was resumed and replaced in the cage.
1K1C renovascular hypertension in mice—A 1K1C renovascular hypertension in 
mice was produced as previously described (35). Briefly, a left lateral abdominal incision is 
used to expose the kidney. A clip (0.12 mm opening) is placed around the left renal artery to 
reduce renal blood flow. Another incision is made in the right lateral abdominal wall, and a 
right nephrectomy is performed. Animals develop volume overload–dependent cardiac 
hypertrophy and renal failure.
Echocardiograph—Transthoracic echocardiography was performed using a 30-MHz 
probe and the Vevo 770 Ultrasound machine (VisualSonics). Mice were lightly anesthetized 
with 1% isoflurane, maintaining heart rate at 400 to 500 beats per minute, and placed in 
dorsal recumbency on a heated 37°C platform. The heart was imaged in the two-dimensional 
mode in the parasternal long-axis view. From this view, an M-mode cursor was positioned 
perpendicular to the interventricular septum and the posterior wall of the LV at the level of 
the papillary muscles. LV free wall thickness in diastole (LVWT d) and in systole (LVWT s) 
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as well as LV diameter in diastole (LVD d) and in systole (LVD s) were measured according 
to the American Society of Echocardiography guidelines. The measurements were taken in 
three separate M-mode images and averaged. EF was calculated using the formula %EF = 
[(LVVD – LVVS)/LVVD] × 100, where LVVD and LVVS are LV volume in diastole and 
systole, respectively.
GapmeR delivery in vivo—GapmeR-Wisper and GapmeR-Scrambled control A 
(Exiqon) were diluted in NaCl 0.9% isotonic solution to obtain the final exact concentration 
(5, 10, or 15 mg/kg) just before the injection. GapmeRs were delivered intraperitoneally 
using a U100 insulin 0.3-ml syringe and a 30-gauge, 8-mm needle.
Primary cell culture and transfection
Methods are described in detail in the Supplementary Materials.
Neonatal mouse CM and fibroblasts—Cells were obtained from neonatal C57BL/6 
mice.
Adult mouse cardiac, lung, and tail fibroblasts—Cells were obtained from 12-week-
old C57BL/6 mice.
Human fibroblasts—Adult human dermal fibroblasts were purchased from Gibco. 
Primary cell cultures of human CFs were obtained by tissue enzymatic digestion with 
collagenase and explant outgrowth from atrial samples, as previously described (58).
GapmeR transfection in mouse primary cell—Adult CFs, neonatal CF, lung 
fibroblasts, and CMs were transfected with 10 nM (if not differently specified in the text) of 
LNA IncRNA GapmeRs (GapmeR-Wisper or scrambled GapmeR or GapmeR-Wisp2; 
Exiqon).
GapmeR transfection in human CFs—Fibroblasts were transfected with 25 nM LNA 
IncRNA GapmeRs (GapmeR-Wisper or scrambled GapmeR; Exiqon).
CRISPR-on assay
CRISPR-based gain of function was used to activate Wisper expression in P19CL6 cells 
(RCB2318; RIKEN Cell Bank). Cells were cultured in Dulbecco’s modified Eagle’s 
medium with 10% fetal calf serum (FCS) and transfected with a component of the 
synergistic activation mediator described by the Zhang laboratory in combination with a 
Wisper-targeting guide RNA engineered to contain two MS2 aptamers [sgRNA(MS2); 
Addgene plasmid no. 61424] and containing the sequence GTCGACTCTGCTATACTCCA. 
Plasmids were transfected at a 1:1 ratio using Lipofectamine 2000 (Life Technologies) 
according to the manufacturer’s instructions. Total RNA was isolated 48 hours after 
transfection using the miRNeasy kit (Qiagen) and subjected to qRT-PCR.
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Cytoplasmic and nuclear compartment fractionation
Adult CFs (2 ×106) were washed twice with cold phosphate-buffered saline (PBS). Nuclear 
and cytoplasmic RNA fractions were isolated using the Cytoplasmic and Nuclear RNA 
purification kit (Norgen Biotek Corp.) according to the manufacturer’s instructions. Total 
RNA was isolated from 1 × 106 adult CFs using the miRNeasy kit (Qiagen) and used as 
input.
Immunohistochemistry
Cardiomyocytes—CMs were transfected with 10 nM GapmeR-Wisper or GapmeR-
Scrambled for 48 hours. Cells were then fixed for 10 min in 4% paraformaldehyde in PBS 
and permeabilized with 0.2% Triton X-100 in PBS. After treatment with blocking buffer 
(PBS containing 0.001% Triton X-100, 1% bovine serum albumin, and 1% FCS), cells were 
incubated overnight at 4°C with anti–α-sarcomeric actinin antibodies (1:400; Sigma). One 
day after, cells were washed three times and incubated for 1 hour at room temperature in the 
dark with conjugated anti-mouse donkey secondary antibodies (1:500, Alexa Fluor 488; Life 
Technology). Nuclei were stained with DAPI (Invitrogen). Unbound antibodies were washed 
out with PBS 0.1% Tween. Subsequently, coverslips were mounted with Fluoromount-G 
(SouthernBiotech) and analyzed with an inverted Axiovision Observer Zl fluorescence 
microscope (Carl Zeiss). Five pictures for each different condition were taken. The 
dimension of the cells was measured using ImageJ. CMs were counted as α-sarcomeric 
actinin–positive and DAPI-positive cells, whereas nonmyocyte cells were counted as α-
sarcomeric actinin–negative and DAPI-positive cells.
Cardiac fibroblasts—Cells were transfected with 5 nM GapmeR-Wisper or GapmeR-
Scrambled for 48 hours. Cells were fixed as described above and incubated overnight at 4°C 
with anti-TIAL antibody (1:200, AM29499; Abeam). One day thereafter, cells were washed 
three times and incubated for 1 hour at room temperature with conjugated anti-rabbit goat 
secondary antibodies (1:250, Alexa Fluor 488; Life Technology). Actin filaments were 
stained using Texas Red-X Phalloidin (1:100, T7471; Life Technologies), and nuclei were 
stained with DAPI (Invitrogen). Unbound antibodies were washed out with PBS 0.1% 
Tween. Subsequently, coverslips were mounted with Fluoromount-G (Southern Biotech) and 
TIAL localization was analyzed with an inverted Axiovision Observer Zl fluorescence 
microscope (Carl Zeiss).
Assessment of cardiac fibrosis
Hearts were harvested from sham-operated and MI mice, and atria and big vessels were 
eliminated. Cardiac tissues were fixed in 4% formalin overnight. Paraffin tissue sections 
were processed for Masson’s trichrome staining using standard histological procedures. The 
percentage of fibrotic tissue was determined by measuring collagen deposition (blue) on 
Masson’s trichrome-stained sections using ImageJ.
RNA pulldown
Biotinylated Wisper sense and Wisper antisense were in vitro transcribed using the T7 or T3 
RNA polymerase (Promega) and Biotin RNA Labeling Mix (Roche) and then purified with 
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Quick Spin columns (Roche) according to the manufacturers’ instructions. Biotinylated 
RNA (4 µg) was denaturated for 5 min at 65°C in RNA structure buffer (10 mM tris-HCl, 10 
mM MgCl2, and 100 mM NH4C1) and cooled to room temperature. In brief, freshly 
harvested CFs were washed in ice-cold PBS. Cells were lysed in 1 ml lysis buffer [25 mM 
tris-HCl (pH 7.4), 150 mM NaCl, 5 mM MgCl2, 0.1 mM EDTA, 0.5% NP-40, 1 mM 
dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride, ribonuclease inhibitor (0.1 U/µ1; 
Promega), and l× protease inhibitor cocktail (Sigma)]. Streptavidin Dynabeads were washed 
in NT2 buffer [50 mM tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MgCl2, 0.05% NP-40,1 mM 
DTT, 20 mM EDTA, 400 mM vanadyl-ribonucleoside, RNase inhibitor (0.1 U/µl; Promega), 
and l× protease inhibitor cocktail (Sigma)] and used to preclear the lysate (20 min at 4°C). 
The precleared cell lysate was incubated with biotinylated RNA along with RNase inhibitor 
(0.1 U/µ1; Promega) and yeast transfer RNA (20 µg/ml; Ambion) for 1.5 hours at room 
temperature followed by addition of 60 µ1 of Streptavidin Dynabeads for 1.5 hours. The 
beads containing the RNA protein complex were washed thrice in NT2 buffer and then were 
directly boiled in SDS-gel loading dye. Retrieved proteins were loaded on a 12% 
polyacrylamide gel in denaturating SDS–polyacrylamide gel electrophoresis (SDS-PAGE) 
buffer and visualized with Candiano colloidal Coomassie staining. Mass spectrometry was 
performed at the Protein Analysis Facility (University of Lausanne, Switzerland). Analysis 
of the pulled-down proteins was performed using Scaffold4. Protein enrichment was 
calculated by Fisher’s exact test.
Western blot of RNA pulldown
Four percent of the samples used for RNA pulldown were used as input. Proteins were 
resolved on 10% SDS-PAGE minigels and transferred to polyvinylidene difluoride 
membranes (Bio-Rad). The membranes were blocked and incubated with primary antibody 
against TIAR (Santa Cruz Biotechnology Inc.) at 4°C overnight. The primary antibody was 
detected using infrared IrDye antibody reagents, and membranes were scanned using the 
Odyssey Infrared Imaging System (LI-COR Biosciences). Protein quantification on the 
scanned Western blots was performed using the software provided with the scanner (LI-
COR Biosciences). Mouse TIAR lysate (20 µg; Santa Cruz Biotechnology) was used as a 
control.
RNA immune precipitation
Cells were harvested in lysis buffer as described previously. Supernatant was precleared with 
Dynabeads G (Invitrogen). The precleared lysate was incubated with normal IgGor with 
anti-TIAR antibody (Santa Cruz Biotechnology) at 4°C overnight followed by addition of 50 
µl of Dynabeads G for 1 hour at 4°C. The immunoprecipitated complexes were washed 
thrice in NT2 buffer and eluted in 500 µ1 of QIAzol. Total RNA extraction and 
complementary DNA synthesis were performed as described before. RT-PCR system 
(Applied Biosystems) was then used to measure expression of Wisper, Wisp2, and Plod2.
Human tissue sampling
The present study conforms to the principles of the Declaration of Helsinki. All subjects 
were duly informed and gave written consent. Samples were collected as previously 
described (46).
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Collagen volume fraction—The fraction of myocardium occupied by collagen was 
quantified as previously described (46). A cluster analysis was performed according to the 
CVF values to define the nonsevere (CVF, <12%; n = 11) and the severe (CVF, >12%; n = 
15) fibrosis groups (46).
Echocardiography analysis—LV mass was measured from M-mode recordings. LV 
mass index was calculated by dividing LV mass by body surface area. LV end-systolic and 
end-diastolic volume indices (LVESVI and LVEDVI, respectively), corresponding to the LV 
volumes corrected by body surface area, and the LVEF were determined in all patients. The 
following pulsed Doppler measurements were obtained: maximum early (VE) transmitral 
velocity in diastole, maximum late (VA) transmittal velocity in diastole, the deceleration 
time of the early mitral filling wave (DT), and the isovolumetric relaxation time (IVRT).
Sequencing of RNA isolated from GapmeR-transfected adult CFs
Total RNA was isolated from adult CF transfected (10 nM, 48 hours) with GapmeR-Wisper 
(n = 4) or GapmeR-Scrambled (n = 4) using the miRNeasy kit (Qiagen). Sequencing 
libraries were prepared according to the Illumina RNA Seq library kit instructions with 
PolyA selection. Libraries were sequenced with the Illumina HiSeq2000 (1 × 100 bp). 
Purity-filtered reads were adapter- and quality-trimmed with Cutadapt (v. 1.3) and filtered 
for low complexity with seq_crumbs (v. 0.1.8). Reads were aligned against the Mus 
musculus. GRCm38.82 genome using STAR (v. 2.4.2a) (59). The number of read counts per 
gene locus was summarized with HTSeq count (v. 0.6.1) (60) using Mus musculus. 
GRCm38.82 gene annotation. Quality of the RNA-seq data alignment was assessed using 
RSeQC (v. 2.3.7) (61). Reads were also aligned to the Mus musculus.GRCm38.82 
transcriptome using STAR (v. 2.4.2a) (59), and the estimation of the isoform abundance was 
computed using RSEM (v. 1.2.19) (62). Statistical analysis was performed for genes and 
isoforms independently in R (R version 3.1.2). Genes/isoforms with low counts were filtered 
out according to the rule of 1 cpm in at least one sample. Library sizes were scaled using 
trimmed mean of M-value (TMM) normalization (EdgeR v 3.8.5) (63) and log-transformed 
with limma voom function (R version 3.22.4). Statistical quality controls were performed 
through pairwise sample correlations, clustering, and sample principal components analysis. 
Replicates cluster together and are well separated between conditions. Differential 
expression was computed with limma (64) by fitting data into a linear model, adding the 
factor for the batch effect, and comparing GapmeR versus control conditions. The P values 
were adjusted for multiple comparisons using the Benjamini-Hochberg method (65), 
controlling for false discovery rate or adjusted P value.
Statistical analysis
GraphPad Software (version 6 or 7) was used for statistical analysis. Data throughout the 
paper are expressed as mean ± SEM. Statistical significance between two columns was 
assessed by two-tailed unpaired Student’s t test; for more than two columns, one-way 
ANOVA [Fisher’s least significant difference (LSD) test] analysis was used. Two-way 
ANOVA (Fisher’s LSD test) was used to evaluate statistical significance between two or 
more groups. Correlation analysis was performed with Pearson (r or r2 values; 95% CI) or 
Spearman (r; 95% CI) test. Significance in percentage of animal survival was calculated with 
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log-rank (Mantel-Cox) test. P values <0.05 were considered significant in all events. 
Individual-level data and exact P values are shown in table S7.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Identification of SE-associated lncRNAs
(A) Selection strategy of novel SE-associated lncRNAs from a genome-wide profiling of the 
cardiac transcriptome after MI. (B) Schematic of an intergenic lncRNA located between two 
PCGs. Heat map showing clustering of heart-enriched intergenic lncRNAs differentially 
expressed after MI (adjusted P < 0.01). (C) Volcano plot of lncRNAs associated with TEs 
(triangle) or with SEs (circle). The x axis shows lncRNAs expression in infarcted versus 
sham-operated animals (log2 fold change) quantified from RNA-seq data; the y axis shows 
adjusted P value. Wisper expression in sham-operated (black bar) and infarcted heart (red 
bar) is expressed in FPKM (fragments per kilobase of exon per million fragments mapped). 
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Bars represent mean ± SEM (n = 4). P value was determined by Student’s t test. (D) qRT-
PCR analysis of SE-associated lncRNAs (SE-lncRNA) and PCG expression in CMs and 
fibro-blasts isolated from neonatal mouse hearts. Data represent fold change ratio (CM/CF) 
mean ± SEM (n = 3). P value was determined by Student’s t test. (E) H3K27Ac signature of 
the locus encompassing Wisper in different human tissues. The red bar highlights the SE 
region.
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Fig. 2. Wisper is enriched in CFs and up-regulated in fibrotic myocardial tissue
(A) Wisper and Wisp2 expression in different mouse tissues quantified by qRT-PCR. Bars 
represent mean expression relative to the heart ± SEM (n = 4). P value was determined by 
one-way analysis of variance (ANOVA) (Fisher’s test). (B) Heat map representation of 
Wisper and fibroblast gene expression (relative to tail fibroblasts) in fibroblasts isolated from 
different tissues. Three independent experiments are shown. P value was determined by one-
way ANOVA (Fisher’s test). (C) Percentage of nuclear (black bar) and cytoplasmic (gray 
bar) RNA concentrations of Wisper, Gapdh, and Tubg1 (cytoplasmic markers), and Neat1 
and Xist (nuclear markers) measured by qRT-PCR after subcellular fractionation in CFs. 
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Data represent mean ± SEM (n = 4). (D) Ejection fraction (ΔEF; green line) and systolic left 
ventricular internal dimension (LVID s; blue line) after MI by echo-cardiography as 
compared to sham. Three different phases of remodeling are highlighted. (E) Expression 
kinetics of Wisper and canonical markers of mal-adaptive cardiac remodeling measured by 
qRT-PCR. Graphs show means normalized to sham ± SEM (n = 6 to 10 animals). P values 
were determined by two-way ANOVA (Fisher’s test). (F) Detection of Wisper expression in 
sham and infarcted heart sections by in situ hybridization. (G) Heat map of correlations of 
expression between Wisper and various genes implicated in postinfarction biological 
processes. Correlations between Wisper and Col1a1, Col3a1, Nppb, and Gata4 are shown as 
examples. Pearson’s correlation test [r2; 95% confidence interval (CI)]. (H) Heat map 
representation of the correlation between Wisper expression in the BZ and 
echocardiographic traits. Pearson’s correlation test (r; 95% CI).
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Fig. 3. Wisper controls CF behavior and survival
(A) Wisper expression in adult CFs after GapmeR transfection at increasing concentrations. 
Bars represent means normalized to control ± SEM (n ≥ 6). P values were determined by 
Student’s t test. (B and H) Gene expression measured by qRT-PCR in adult CFs (B) or lung 
fibroblasts (FBs) (H) after transfection with GapmeRs (10 nM, 48 hours; n ≥ 5) targeting 
Wisper (GM-Wisper) or scrambled GapmeRs (GM-Scr). P values were determined by two-
way ANOVA (Fisher’s test). (C and I) Proliferation of adult CFs (C) or lung fibroblasts (I) 
after GapmeR transfection (10 nM) quantified by [H3]thymidine incorporation. Data are 
expressed as mean counts per million (cpm) ± SEM (n > 3). P values were determined by 
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two-way ANOVA (Bonferroni’s test). (D and J) Migration of adult CFs (D) or lung 
fibroblasts (J) after GapmeR transfection (10 nM) measured using a wound closure assay. 
Representative pictures are shown. Scale bars, 100 µM. Graphs show the percentage of 
wound closure at each time point ± SEM (n ≥ 3). P values were determined by two-way 
ANOVA (Bonferroni’s test). (E and K) Representative fluorescence-activated cell sorting 
(FACS) analysis of annexin V-positive adult CFs (E) or lung fibroblasts (K) after GapmeR 
transfection (10 nM). Graphs show the percentage of apoptotic cells ± SEM (n = 3). P values 
were determined by Student’s t test. (F) Bax expression–to-Bcl2 expression ratio in adult 
CFs after GM-Wisper or GM-Scr transfection (10 nM, 48 hours). Bars represent means ± 
SEM (n = 3). P values were determined by Student’s t test. (G) Wisper expression in adult 
CFs and lung fibroblasts after GM-Wisper transfection (10 nM). Bars represent means 
normalized to GM-Scr ± SEM (n ≥ 5). P values were determined by Student’s t test.
Micheletti et al. Page 29
Sci Transl Med. Author manuscript; available in PMC 2017 October 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. Regulation of CF gene programs by Wisper
(A) Hierarchical clustering of PCGs differentially expressed in adult CFs after transfection 
with GapmeRs targeting Wisper (GM-Wisper) or scrambled GapmeRs (GM-Scr) as assessed 
by RNA-seq (fold change, >2; adjusted P < 0.05). (B and C) GO terms linked to biological 
processes and mouse phenotypes for the up-regulated (B) or down-regulated (C) PCGs in 
Wisper-depleted adult CFs. (D) Heat map representing functional sets of PCGs modulated 
by GapmeR-mediated Wisper depletion in CFs. PCGs are clustered based on biological and 
cellular functions. (E) Expression of relevant fibrosis-related genes measured by qRT-PCR 
in P19CL6 cells after CRISPR-on–mediated Wisper induction (Wisper targeting sgRNA; 
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orange bar) as compared to control (none; white bar). Mean ± SEM (n = 3). P values were 
determined by Student’s t test. (F) GapmeR-induced depletion of Wisp2 in adult CFs (10 
nM, 48 hours). Expression of relevant fibrosis-related PCGs. Bars show means normalized 
to control (GM-Scr) ± SEM (n ≥ 3). P values were determined by Student’s t test.
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Fig. 5. Wisper is associated with TIA1-related protein and regulates lysyl hydroxylase 2 
expression
(A) Proteins enriched after pulldown using biotinylated Wisper and identified by mass 
spectrometry. The x axis shows the protein enrichment in the Wisper group as compared to 
the control antisense Wisper group; the y axis shows the −log P value determined by 
Fisher’s test. (B) Amino acid composition of the protein TIAR. The detected amino acids by 
mass spectrometry are highlighted in yellow (103 of 392 amino acids; 26% coverage). (C) 
Protein quantification of TIAR by Western blotting in the pulled-down protein fraction. 
Purified TIAR is used as positive control. Graph shows means ± SEM (n = 3). P values were 
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determined by Student’s t test. A.U., arbitrary units. (D) Quantification of RNA after 
immunoprecipitation using an immunoglobulin G (IgG) directed against TIAR or a control 
IgG. Protein lysate was produced from CFs after transfection with GapmeRs targeting 
Wisper (GM-Wisper) or scrambled GapmeRs (GM-Scr) (10 nM, 48 hours). Graph shows 
means ± SEM (n = 6). P values were determined by two-way ANOVA (Fisher’s test). Ab, 
antibody. (E) Plod2 expression in adult CFs after GM-Wisper, GM-Wisp2, or GM-Scr 
transfection (10 nM, 48 hours). Bars represent means ± SEM (n = 3). P values were 
determined by one-way ANOVA. (F) Immunohistochemistry analysis of TIAR expression in 
CFs transfected with GapmeRs targeting Wisper (GM-Wisper) or left untreated (none; 10 
nM, 48 hours). TIAR, green; actin, red; 4’,6-diamidino-2-phenylindole (DAPI), blue. (G) 
Confocal microscopy analysis of TIAR subcellular localization in CFs treated as in (F). (H) 
Percentage of CFs with nuclear TIAR staining after GM-Wisper treatment at various doses. 
Bars represent means ± SEM (n > 6). P values were calculated by two-way ANOVA 
(Fisher’s test).
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Fig. 6. Therapeutic depletion of Wisper inhibits cardiac fibrosis and improves function
(A) Overview of the experimental setup with injections of GapmeRs targeting Wisper (GM-
Wisper; 5 mg/kg) or scrambled GapmeRs (GM-Scr) at 2 and 9 days after Ml. 
Echocardiography was performed 7 and 28 days after the surgery. The cross indicates time 
of sacrifice and tissue collection (sham, n = 6; MI, n = 9). (B and C) Expression of Wisper 
(B) and fibrotic/ stress genes (C) after GapmeR injection (white, GM-Scr; light blue, GM-
Wisper) in sham-operated and MI mice 28 days after surgery. Bars represent means 
normalized to sham GM-Scr ± SEM. P values were determined by two-way ANOVA 
(Fisher’s test). (D) M-mode images of the left ventricle (LV) of GapmeR-injected mice 28 
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days after MI. (E) Echocardiographic assessment of cardiac dimension (LVID d, diastolic 
left ventricular internal dimension; IVS d, diastolic intraventricular septum) and function 
(FS%, fractional shortening). Graphs show means normalized to the average values of sham 
± SEM. P values were determined by two-way ANOVA (Fisher’s test). (F) Ratio of heart 
weight (HW) to tibial length (TL) in GapmeR-injected sham and MI mice. P values were 
determined by two-way ANOVA (Fisher’s test). (G) Fibrotic tissue quantification by 
Masson’s trichrome staining on heart sections. Graph shows the percentage of cardiac 
fibrosis as measured by ImageJ (n ≥ 6). Bars represent means normalized to sham GM-Scr ± 
SEM. P values were determined by two-way ANOVA (Fisher’s test). (H) Correlation 
analysis between the percentage of cardiac fibrosis and Wisper, Colla1, and CoBa1 
expression. Pearson’s correlation test (r, 95% CI). (I) Effect of GapmeR injection on 
survival after Ml.
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Fig. 7. WISPER, a functionally conserved human ortholog of mouse Wisper
(A) Box plot representation of the CVF in the heart of the nonsevere (n = 11) and severe 
fibrosis (n = 15) groups of patients affected by AOS. The line indicates the CVF cutoff value 
used to differentiate the two groups (12%). Box plots showing WISPER and WISP2 relative 
expression analyzed by qRT-PCR in cardiac biopsies from the two different fibrotic groups. 
Data show the mean, all the individual values, and the minimal to maximal variation. P 
values were determined by Student’s t test (compared to nonsevere fibrosis group). (B) 
Correlation analysis between the CVF and WISPER and WISP2 expression quantified by 
qRT-PCR. Pearson’s correlation test (r; 95% CI). (C) Time course of WISPER and WISP2 
expression in differentiating human CFs [red, cardiac fibroblast (FBs)] and dermal FBs 
(green). Graphs show means normalized to control ± SEM (n = 6 to 14). P values versus 
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control were determined by one-way ANOVA. (D) Correlation analysis between WISPER 
expression and COL1A1, COL3A1, FN1, and aSMA expression in differentiating human 
CFs. Spearman’s correlation test (r; 95% CI). (E) Effect of GapmeR-induced WISPER 
depletion (25 nM, 48 hours) on WISP2 and fibroblast gene expression in human CFs. Bars 
show mean ± SEM (n = 3). P values were determined by Student’s t test. (F) Effect of 
GapmeR-induced WISPER depletion (25 nM, 48 hours) on PLOD2 expression in human 
CFs. Bars show mean ± SEM (n = 3). P values were determined by Student’s t test.
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